
Nearly 7 million people in Taiwan suffer from fatty liver disease, making it the most common type of liver disease in the country. The condition is also highly associated with cardiovascular disease, cirrhosis, and even liver cancer. But now there are new breakthroughs in treatment. The Advancing Clinical Treatment of Liver Disease association, or ACT-LD, has introduced a “traffic light” system of metabolic indicators to help the public to assess their liver health.
Indulging in sugary and fatty foods is a common pitfall for many. And with stagnant lifestyles that prioritize lying down over sitting and sitting over standing, be careful—you might be at risk of developing fatty liver disease.
Kao Jia-horng
ACT-LD president
In Taiwan, about one-third of people have fatty liver disease. Of them, approximately 10% will develop inflammation associated with fatty liver. We know that inflammation is a key stop on the way to cirrhosis and liver cancer. Therefore, as soon as there’s inflammation, you should go consult a specialist.
There are nearly 7 million people in Taiwan with fatty liver disease, making it the most common liver affliction in Taiwan. It’s also a critical indicator for serious cardiovascular disease and liver cancer. For people with liver fibrosis, there has long been a lack of effective treatments. But fortunately, new medical breakthroughs have emerged.
Liu Chun-jen
NTU Hospital physician
After Phase III large-scale clinical trials, it has been confirmed that this treatment can effectively improve inflammation associated with fatty tissue and fibrosis scarring. In February, we obtained a trial permit from the Ministry of Health and Welfare. This is a significant breakthrough.
Fatty liver inflammation often has no obvious symptoms in the early stages, making it easy to miss the optimal treatment window. To help people take an active role in monitoring their liver health, check out ACT-LD’s traffic light system for metabolic indicators.
For more Taiwan news, tune in:
Mon to Fri at 9:30 pm on Channel 152
Tue to Sat at 1 am on Channel 53
#liverdisease #fattyliverdisease #health #publichealth #cirrhosis #doctors #ACT-LD #livercancer
全台脂肪肝患者逼近700萬人,不僅是國內最常見的肝臟疾病,也與心血管疾病、肝硬化甚至肝癌高度相關,現在醫療上有了新突破,台灣肝病醫療策進會,也推出紅、黃、綠燈行動分級,列出代謝指標,協助民眾有效判斷肝臟健康。
高糖、高油,一不小心放縱進食,現代人的通病還有,能坐就不站,能躺就不坐,生活習慣不良,小心脂肪肝找上門。
[[台灣肝病策進會會長 高嘉宏]]
“在台灣可能大概有,三分之一的人是有脂肪肝,這裡面大概有接近十個百分比,可能會出現脂肪肝炎,我們也知道說脂肪肝炎,就是邁向這個脂肪肝硬化,跟肝癌的非常重要的一步,所以一旦有這個脂肪肝炎的時候,那就應該要去找,這個專科醫師做這個諮詢”
全台脂肪肝患者逼近700萬人,不只是國人最常見肝病,也是心血管重症與肝癌的危機指標,針對肝纖維化患者,過去長期缺乏治療有效藥物,好在現在醫療上有了新的突破。
[[台大醫學院內科部教授 劉俊人]]
“經過第三期大型的臨床試驗,實際上已經證實可以用來改善跟脂肪相關的發炎,還有纖維結疤的情形,二月也順利拿到這個衛福部的一個試用的一個許可證,這是一個非常大的突破”
脂肪肝炎早期沒有明顯症狀,可能因此錯過治療黃金時機,台灣肝病醫療策進會,也推出紅、黃、綠燈行動,列出代謝指標,幫助民眾一起把關,肝臟健康。
更多新聞內容,請鎖定:
民視台灣台(152頻道)週一至週五晚上9:30
民視新聞台(53頻道)週二至週六凌晨1:00
Related News